Kivorent News

Sunday, November 22, 2026

Health techLooking back

Utah lets an AI write acne prescriptions, with a state contract as the guardrail

Utah's Office of Artificial Intelligence Policy has let Nolla Health's app issue first-time acne prescriptions under a staged agreement, after earlier deals let Doctronic's AI renew refills. Here is what those agreements allow, and who checks the work.

Docket, covering health regulation and AI in care
Published , 3 min read

12 weeksminimum before Nolla's AI can reach its lightest-review stage

This is a look back at an event from . We wrote it on November 21, 2026, from the sources listed at the end.

What to know

  • Nolla Health says its Nolla Derm app is the first in the U.S. authorized by a state regulator to issue an initial prescription by AI, for adult acne in Utah.
  • The AI picks from pre-approved topical treatment plans; physicians review every prescription before it is sent for the first 100 patients.
  • An earlier Utah agreement lets Doctronic's AI renew existing prescriptions, but not write new ones or handle controlled substances.

Nobody in Washington approved the first American AI to write a new prescription. A state office in Salt Lake City did, by contract. That distinction is the whole story.

On October 5, Nolla Health said its Nolla Derm app had become the first organization in the country authorized by a state regulator for AI to issue an initial prescription, not just a refill. The regulator is Utah's Office of Artificial Intelligence Policy, which Utah Business describes as the agency that grants companies temporary relief from licensing rules. This isn't an FDA clearance, and nothing we read mentions the FDA. It is a regulatory mitigation agreement: relief from state rules, in exchange for conditions.

What the AI is allowed to do

According to Nolla, the app serves Utah residents 18 and older with acne. After identity checks, consent, a questionnaire and a five-angle face scan, the AI selects from pre-approved topical treatment plans. Severe acne, pregnancy and anything outside the pilot go to a physician or to in-person care. Healthcare Dive describes the same scope as mild-to-moderate acne and a short list of topical drugs.

So this is a menu, not a blank prescription pad. The AI's real job is triage: deciding who fits the menu and which item on it applies.

The stages, and the math

Nolla's post lays out three stages. In the first, two licensed physicians independently approve every AI-written prescription before the patient gets it, for the first 100 patients and at least four weeks. In the second, up to 500 patients, the AI prescribes directly and a physician reviews every case afterward, at least weekly, for at least eight weeks. In the third, physicians review at least 10% of prescriptions each month, plus every escalation and side effect. Moving up a stage takes written state approval and safety targets, including 95% agreement with physicians and zero serious adverse events.

Add the minimums and the AI can't reach its lightest-review stage until at least 12 weeks after launch. From October 5, that's December 28 at the earliest, and only if the state signs off twice.

One caution on the details. Chief Healthcare Executive's account differs from the company's: one reviewing physician in stage one, daily review in stage two, a weekly sample in stage three. We've used Nolla's own description because it's the party to the agreement, but the signed agreement is what would settle it, and we haven't read it.

The refill precedent, and the board that objected

Nolla isn't Utah's first health AI deal. The state's agreement with Doctronic, posted by the AI office, lets its AI process 30-, 60- or 90-day renewals of medications a licensed provider already prescribed. The same page says it won't issue new prescriptions, handle controlled or addictive substances, or change treatment plans.

That deal drew pushback. Healthcare Dive reported that Utah's medical licensing board asked for the Doctronic pilot to be suspended, saying it "had not been informed of the pilot." The state declined. Nolla, per Chief Healthcare Executive, met with the medical board before launch, which reads like a lesson learned.

Healthcare Dive reported that the same October slate also approved August AI, for renewing prescriptions in chronic conditions, and Expect Fitness, for virtual pelvic floor therapy.

What's still unanswered

Who pays when the AI gets it wrong? Healthcare Dive cites Stanford law professor Michelle Mello's view that Doctronic's contract is murky about responsibility for prescribing errors, and nothing we read describes Nolla's liability terms. The 96% clinician-agreement figure is Nolla's own, with no published method.

Federal law is the other open edge. Utah can relax its own licensing rules; it can't relax the FDA's. Software that diagnoses acne from photos and picks a treatment looks a lot like a medical device, and whether the agency weighs in is the question to watch. For how that line usually gets drawn, see our explainers on FDA clearance, approval and De Novo and when AI scribes become devices. For the federal prescribing rules that still apply, see how telehealth prescribing works, and for Washington's latest look at AI in care, our story on GAO's chatbot spotlight.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

AI law and policyDigital health and AI in careAI agents

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.